Search Results
Your search for ,dUe matches 5584 pages
Showing 3901 - 3950In Vitro Fertilization Not Associated With Increased Risk of Breast Cancer in Dutch Study
Among women undergoing fertility treatment in the Netherlands between 1980 and 1995, the use of in vitro fertilization (IVF) compared with non-IVF treatment was not associated with increased risk of breast cancer after a median follow-up of 21 years, according to a study published by van den...
Fentanyl Nasal Spray Now Available at a Dose of 300 µg for Treatment of Breakthrough Cancer Pain
Fentanyl (Lazanda) nasal spray, a schedule II narcotic, is now available at a 300-µg dose to treat breakthrough cancer pain, offering physicians another titration option for dosing flexibility. The new strength can help physicians more easily and accurately target the appropriate dose for patients, ...
Lung Cancer Screening: Beneficial for Certain Populations but Not Without Controversy
The National Cancer Policy Forum of the National Academies of Sciences took up the issue of lung cancer screening at its mid-June workshop. Greta Massetti, PhD, Associate Director for Science, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (CDC), and chair of ...
ASCO 2016 Guidelines for the Treatment of Pancreatic Cancer: Why Another Guideline?
The 5-year survival rate of those diagnosed with pancreatic cancer remains stubbornly fixed around 5%. Even in the 20% of cases in which surgical resection is undertaken for curative intent, the 5-year survival rate after surgery is 20% to 30%. As we make progress in other cancers with decreasing...
Road to Successful Use of Real-World Evidence for Drug Development Is Long and Rocky
Friends of Cancer Research (Friends) has been a leader in the push for better and faster cancer drug development. Now it is tackling the use of real-world evidence in clinical trials. This is the report of a meeting on the subject that took place on June 16 in Washington, DC.1 Real-world evidence...
Benefit Strongly Suggested With Hormonal Maintenance in Low-Grade Serous Carcinoma
In patients with low-grade serous carcinoma, maintenance hormonal therapy reduced the risk of recurrence by 77%, compared with surveillance, in a retrospective cohort from The University of Texas MD Anderson Cancer Center. The study was reported by David Marc Gershenson, MD, at the 2016 ASCO...
PHEREXA: Benefit for Second-Line Pertuzumab Questionable
In the second-line metastatic breast cancer setting, the addition of pertuzumab (Perjeta) to trastuzumab (Herceptin)/capecitabine did not significantly improve progression-free survival, results of the phase III PHEREXA trial showed.1 This is the first randomized trial to evaluate the efficacy of ...
Studies Suggest Bright Future for Combination Immunotherapy in Advanced Melanoma, but Questions Remain
Two studies presented at the 2016 ASCO Annual Meeting focused on the use of combination immunotherapy in the treatment of patients with advanced melanoma. Updated results from the phase III CheckMate 067 trial centered on the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) compared...
No Survival Benefit for Cabozantinib Reported in Previously Treated Metastatic Castration-Resistant Prostate Cancer
Smith et al found no improvement in overall survival with cabozantinib (Cometriq) vs prednisone in patients with previously treated metastatic castration-resistant prostate cancer, in the phase III COMET-1 trial reported in the Journal of Clinical Oncology. Cabozantinib, which inhibits MET, VEGF...
Results of Two Practice-Changing Breast Cancer Trials Upheld
Results of two pivotal breast cancer trials reported at the 2016 ASCO Annual Meeting confirmed the practice-changing findings that resulted from earlier findings. PALOMA-2 The phase III PALOMA-2 trial confirmed results from the smaller, open-label phase II PALOMA-1 trial that led to the U.S. Food...
Comparison of Chemotherapy Regimens in Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma
FOLFOX (oxaliplatin, leucovorin, fluorouracil [5-FU]) seems to be a safer and more reliable regimen than ECF (epirubicin, cisplatin, 5-FU) and irinotecan/cisplatin as a backbone for treatment in future studies of metastatic esophageal and gastroesophageal junction cancers. This finding from the...
Early Results Find Pembrolizumab Active in Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Findings in a classical Hodgkin lymphoma cohort in the phase Ib KEYNOTE-013 trial, reported by Armand et al in the Journal of Clinical Oncology, indicate that pembrolizumab (Keytruda) is active in patients with disease progressing on or after brentuximab vedotin (Adcetris) treatment. Study Details ...
Obesity Linked to Increased Risk of Multiple Myeloma Mortality in African Americans
Obesity may be associated with an increased risk for death from multiple myeloma in African Americans, according to a study reported by Sonderman et al in the Journal of the National Cancer Institute. Multiple myeloma incidence and mortality rates have been reported to be twice as high among...
Heart Failure After First Heart Attack Associated With Increased Risk of Cancer
Patients who develop heart failure after their first heart attack have a greater risk of developing cancer when compared to first-time heart attack survivors without heart failure, according to a study published by Hasin et al in the Journal of the American College of Cardiology. Heart failure...
First-Line Nivolumab Monotherapy Active in Advanced NSCLC
As part of the phase I CheckMate 012 study reported by Gettinger et al in the Journal of Clinical Oncology, nivolumab (Opdivo) monotherapy was found to be active as first-line treatment in advanced non–small cell lung cancer (NSCLC). The study is also examining first-line nivolumab plus...
Prevention Needed to Stem Global Rise in Human Papillomavirus–Related Anal Cancer
The incidence rate of human papillomavirus (HPV)-related anal cancer and its precursor lesion, anal intraepithelial neoplasia, is rising in the United States and globally. Although 5-year survival rates in localized disease are generally favorable, survival in metastatic disease remains poor,...
Managing Upper Extremity Dysfunction in Breast Cancer Survivors
With an increased number of breast cancer survivors and patients with metastatic disease living longer, it is imperative for oncology care providers to manage issues of new and chronic upper extremity dysfunction as a result of the malignancy itself or its treatment. As one of my patients...
Fentanyl Nasal Spray Now Available at a Dose of 300 μg for Treatment of Breakthrough Cancer Pain
Fentanyl (Lazanda) nasal spray, a schedule II narcotic, is now available at a 300-μg dose to treat breakthrough cancer pain, offering physicians another titration option for dosing flexibility. The new strength can help physicians more easily and accurately target the appropriate dose for...
Relapse of Leukemia After Bone Marrow Transplantation: Cytomegalovirus Infection Has No Protective Effect
Recent studies on a small number of patients with leukemia treated with bone marrow transplantation have suggested that the presence of the common cytomegalovirus (CMV) in patients or their donors may protect against relapse or even death after the transplant. A large international study published...
Women’s Networking Center Addresses Gender Gap, Provides Mentorship for Annual Meeting Attendees
ASCO is committed to providing all oncologists with opportunities for professional development that will maximize their career success. In response to the recognized career gender gap for women in oncology, ASCO included a number of initiatives in the 2016 Annual Meeting program. In its 2nd year,...
FDG–PET Evaluates Immunotherapy for Non–Small Cell Lung Cancer
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented study findings on a means of evaluating an immunotherapy for non–small cell lung cancer (NSCLC).1 Due to NSCLC’s relative insensitivity to chemotherapy, the use of immunotherapies,...
Expert Point of View: Charles Ryan, MD
“These are important data. It is safe to envision a future where atezolizumab [Tecentriq] can be used first-line. These were cisplatin-ineligible patients, and many patients fall into this category, especially the elderly. Platinum-ineligibility is a big problem due to comorbidities,” explained...
Atezolizumab Promising in Cisplatin-Ineligible Metastatic Bladder Cancer
Atezolizumab (Tecentriq), an anti–programmed cell death ligand 1 (PD-L1) inhibitor, achieved durable responses as first-line treatment in cisplatin-ineligible patients with metastatic urothelial carcinoma in a primary analysis of a phase II trial. These data represent an unmet need, because...
Expert Point of View: Elizabeth Mittendorf, MD, PhD
The discussant of these studies was Elizabeth Mittendorf, MD, PhD, Associate Professor of Breast Surgical Oncology at the University of Texas MD Anderson Cancer Center, Houston. Dr. Mittendorf noted that approximately 3% of U.S. breast cancer patients present with de novo stage IV disease. For...
Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival in Rituximab-Refractory NHL
In the phase III GADOLIN trial reported in The Lancet Oncology, Sehn et al found that adding the anti-CD20 antibody obinutuzumab (Gazyva) to bendamustine (Bendeka, Treanda) increased progression-free survival in patients with rituximab-refractory indolent non-Hodgkin lymphoma (NHL). Outcomes in...
Is Nivolumab Active in Recurrent Small Cell Lung Cancer?
In the phase I/II CheckMate 032 study, nivolumab (Opdivo) alone and with ipilimumab (Yervoy) demonstrated activity in patients with small cell lung cancer (SCLC) progressing after at least one previous platinum regimen, as reported in The Lancet Oncology by Antonia et al. Study Details In the...
Moonshot Program for … Compassion
A 65-year-old patient with widely metastatic pancreatic cancer was emergently transferred to our facility in the early hours of the morning with free air suggestive of a perforated viscus. The patient is from a small town several hundred miles away from our academic center, which can be quite...
Geriatric Oncology in Asia: The Dawn of a New Era in Cancer Care
Asia is currently experiencing an unprecedented rate of growth in its aging population. This “silver tsunami” has translated into a burgeoning number of older patients with cancer, as cancer is a disease of aging. However, unlike their Western counterparts, elderly patients with cancer in Asia are ...
Geriatric Patients With Cancer and the Problem of Polypharmacy
Older patients with cancer generally have multiple comorbidities, with each often requiring separate medications. Studies have shown that polypharmacy and inappropriate drug use are prevalent among older cancer patients, leading to an enormous amount of preventable adverse events, many requiring...
Sequential Nivolumab/Ipilimumab Appears More Active Than Reverse Sequence in Advanced Melanoma
In the phase II CheckMate 064 trial reported in The Lancet Oncology, Weber et al found that sequential nivolumab (Opdivo)/ipilimumab (Yervoy) was more active than the reverse sequence (ipilimumab/nivolumab) in patients with advanced melanoma. Study Details In the open-label study, 138 patients...
Dabrafenib Plus Trametinib Shows Activity in BRAF V600E–Mutant Metastatic NSCLC
In a phase II trial reported in The Lancet Oncology, Planchard et al found that combined MAPK pathway inhibition with the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) resulted in a high response rate in patients with BRAF V600E–mutant non–small cell...
Tackling the Symptoms of Long-Term Fatigue and Insomnia in Cancer Survivors
Fatigue and sleep disruption are common occurrences for most patients diagnosed with cancer. Simply having a serious physical illness like cancer along with its associated pain, hospitalization, and treatment, as well as the attendant psychological impact, all contribute to the onset of fatigue...
European Demand for Radiotherapy Expected to Rise Approximately 16% Over Next Decade
The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published by Borras et al in Radiotherapy and Oncology.1 These projections came...
Cervical Cancer Prevention Badly Needed in India
With the advent of the Papanicolaou (Pap) test and population-based screening, along with the development of the human papillomavirus (HPV) vaccine, cervical cancer has become a largely preventable disease for many. However, in India, cervical cancer is a leading cause of cancer mortality. To...
Medical Decision-Making: At the Heart of Care for Older Patients With Cancer
Although oncology has moved toward a personalized approach to care, medical decision-making within the context of multidisciplinary care has broad public health implications. To shed light on this and other relevant issues, The ASCO Post recently spoke with William Dale, MD, PhD, of the University ...
Once-Daily Radiation (66 Gy) Appears No Better Than Twice-Daily Radiation (45 Gy) for Small Cell Lung Cancer
A schedule of once-daily radiation therapy (66 Gy) was no better than a twice-daily schedule (45 Gy) for optimization of chemoradiotherapy in patients with limited-stage small cell lung cancer (SCLC), according to the eagerly anticipated results of the phase III CONVERT trial, presented at the...
USPSTF Issues New Recommendations for Colorectal Cancer Screening
As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) has issued new recommendations for colorectal cancer screening. In brief, the USPSTF recommends colorectal cancer screening starting at age 50 years and continuing until age 75 years (grade A recommendation = “The USPSTF...
Trastuzumab Biosimilar Shows Efficacy and Safety Comparable to Reference Product in Phase III HERITAGE Trial
A new biosimilar version of the monoclonal antibody trastuzumab (Herceptin) is getting close to the finish line in the race to develop biosimilars in oncology. The new antibody, MYL-1401O, demonstrated comparable efficacy and safety compared with trastuzumab as front-line treatment of women with...
Supporting Policy to Reduce Tobacco-Related Deaths
One billion lives. That is the estimated human death toll of tobacco use in the 21st century.1 Tobacco use is the leading cause of preventable death worldwide—20% of all deaths and 30% of cancer deaths in the United States are linked to tobacco use.2,3 Impacting this preventable public health...
Autologous Stem Cell Transplantation Offers Safe, Effective Option for Patients With HIV-Associated Lymphoma
A phase II, multicenter trial published by Alvarnas et al in Blood challenges the generally held belief that individuals with human immunodeficiency virus (HIV) and aggressive lymphoma are not candidates for standard treatment. According to the researchers, people with HIV-associated lymphoma who...
Is Anti–PD-L1 Antibody Durvalumab Active in Advanced Urothelial Bladder Cancer?
In a phase I/II study reported in the Journal of Clinical Oncology, Massard et al found that the anti–PD-L1 (programmed cell death ligand 1) antibody durvalumab was active in patients with previously treated advanced urothelial bladder cancer. Objective response appeared to be confined to...
Final Results of METEOR Trial Show Cabozantinib Improves Overall Survival vs Everolimus in Advanced RCC
As reported by Choueiri et al in The Lancet Oncology, the final results of the phase III METEOR trial indicate significantly improved overall survival with cabozantinib (Cabometyx) vs everolimus (Afinitor) in patients with advanced renal cell carcinoma (RCC) that had progressed after previous...
SNMMI 2016: FDG-PET Evaluates Immunotherapy for Non–Small Cell Lung Cancer
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a means of evaluating an immunotherapy that fights off non–small cell lung cancer (NSCLC) by strengthening a patient’s own immune system (Scientific Paper 134). Due to...
Study Finds Pembrolizumab Active in Advanced Head and Neck Cancer
As reported by Seiwert et al in The Lancet Oncology, the monoclonal antibody pembrolizumab (Keytruda) showed activity in patients with programmed cell death ligand 1 (PD-L1)–positive recurrent or metastatic squamous cell carcinoma of the head and neck in the phase Ib KEYNOTE-012 study. Study ...
ASCO 2016: Hispanic and Black Young Adults With Cancer May Be More Likely to Die of Their Disease
Hispanic white and non-Hispanic black cancer patients between ages 15 and 29 may be more likely than same-aged white patients to die of their disease, according to a University of Colorado Cancer Center study presented by Colton et al at the 2016 ASCO Annual Meeting (Abstract 6557). The finding is...
The Importance of Listening to Patients
My experience with cancer, or more accurately, cancers, is complicated. In 2002, after returning from a medical mission to Honduras, I noticed a bean-sized lymph node above my left clavicle. As an oncology-certified nurse, I knew not to ignore any unusual nodules that pop up on the body and asked...
The Best HCAHPS Score: A Rodeo Invitation
An otherwise healthy, actively working, independent 60-year-old patient came to us with a several months’ history of abdominal pain. He had been seen by other physicians prior to coming to us for a second opinion. Our workup revealed a large cystic lesion emanating from the pancreas but involving ...
Low-Dose Chemical Exposure and Cancer
According to estimates from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), environmental toxic exposures are responsible for between 7% and 19% of human cancers. However, the 2008–2009 President’s Cancer Panel Annual Report estimated that the “true...
Increased Survival and Toxicity With Docetaxel, No Benefit of Zoledronic Acid, When Added to First-Line Hormone Therapy in Prostate Cancer
As reported in The Lancet by Nicholas D. James, BSc, MBBS, PhD, of the University of Warwick, and colleagues, survival results of the STAMPEDE trial, which used a multiarm, multistage seamless phase II/III design, provide little evidence of benefit of zoledronic acid and showed increased survival ...
SIRIUS Trial Heralds a New Era of Promise in Treating Resistant Myeloma
Multiple myeloma cells uniformly overexpress CD38.1 Daratumumab (Darzalex), a CD38-targeting human IgG1 kappa monoclonal antibody, has been evaluated in a series of phase I/II trials involving patients with relapsed or relapsed and refractory myeloma who have received at least two or more prior...
